Comparison of Safety and Efficacy of TOCOSOL(R) Paclitaxel Versus Taxol(R) for Treatment of Metastatic Breast Cancer
NCT ID: NCT00251095
Last Updated: 2009-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
821 participants
INTERVENTIONAL
2005-09-30
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC
NCT00201435
Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer
NCT05207514
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
NCT00028873
Docetaxel or Paclitaxel in Treating Women With Unresectable Locally Advanced or Metastatic Breast Cancer
NCT00006120
Paclitaxel or Docetaxel in Treating Women With Advanced Breast Cancer
NCT00002662
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Taxol
Taxol 80mg/m2/week
Taxol
TOCOSOL
TOCOSOL Paclitaxel
TOCOSOL Paclitaxel
100 mg/m2/week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Taxol
TOCOSOL Paclitaxel
100 mg/m2/week
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stage IV (M1) disease
* Adult (18 years of age or older) patients
Exclusion Criteria
* Patients whose tumor tissue is known to show over expression of HER2/neu
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Achieve Life Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
OncoGenex Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States
Desert Hematology Oncology Medical Group
Rancho Mirage, California, United States
Stockton Hematology Oncology
Stockton, California, United States
Florida Cancer Specialists
Fort Myers, Florida, United States
Mountain State Tumor Institute
Boise, Idaho, United States
Oncology Care Associates
Saint Joseph, Michigan, United States
Southfield Oncology Institute, Inc
Southfield, Michigan, United States
Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Essex Oncology of North Jersey
Belleville, New Jersey, United States
Mid Dakota Clinic
Bismarck, North Dakota, United States
Hematology Oncology Consultants, Inc
Columbus, Ohio, United States
Chattanooga Oncology & Hematology Associates, PC
Chattanooga, Tennessee, United States
The Sarah Cannon Research Institute
Nashville, Tennessee, United States
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SON-8184-1075
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.